Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex

Blood (2019) 134 (Supplement_1): 1230.

https://doi.org/10.1182/blood-2019-130759

Published: 2019

Journal Articles

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia

Huafeng Wang, MD, Jie Sun, PhD, Dandan Zhao, MD, Hongyan Tong, Herman Wu, BS, Xia Li, PhD, Yingwan Luo, MD, Dan Dong, PhD, Tinisha McDonald, MS, Anthony Stein, MD, Monzr M. Al Malki, MD, Flavia Pichiorri, PhD, Nadia Carlesso, MD, Ya-Huei Kuo, PhD, Bin Zhang, PhD, Guido Marcucci, MD, Ling Li, PhD, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 1707.

https://doi.org/10.1182/blood-2019-130375

Published: 2019

Journal Articles

Inflammatory consequences of inherited disorders affecting neutrophil function

Mary C. Dinauer

Blood (2019) 133 (20): 2130–2139.

https://doi.org/10.1182/blood-2018-11-844563

Published: 2019

Journal Articles

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 232.

https://doi.org/10.1182/blood-2018-99-116838

Published: 2018

Journal Articles

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2018) 132 (Supplement 1): 231.

https://doi.org/10.1182/blood-2018-99-110465

Published: 2018

Journal Articles

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Blood (2018) 132 (14): 1526–1534.

https://doi.org/10.1182/blood-2018-05-852566

Published: 2018

Includes: Supplemental data

Journal Articles

Normal Hematopoiesis Is Dependent on the Expression of U2af1, a Spliceosome Gene Commonly Mutated in MDS

Brian Wadugu, BA, Amanda Heard, Joseph Bradley, BS, Matthew Ndonwi, PhD, Matthew J. Walter, MD

Blood (2017) 130 (Supplement 1): 3747.

https://doi.org/10.1182/blood.V130.Suppl_1.3747.3747

Published: 2017

Journal Articles

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Cody Cody Ashby, PhD, Michael Bauer, PhD, Owen W. Stephens, Christopher P. Wardell, PhD, Ruslana G. Tytarenko, MS, Aneta Mikulasova, PhD, Purvi Patel, Shayu Deshpande, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Niels Weinhold, PhD, Leo Rasche, MD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 3032.

https://doi.org/10.1182/blood.V130.Suppl_1.3032.3032

Published: 2017

Journal Articles

Importance of Mitochondrial Metabolism As a Selective Therapeutic Approach in Chronic Lymphocytic Leukemia Patients

Subir Roy Chowdhury, MD PhD, Saleh Ryan, BSc, Donna Hewitt, R.N., Mandy Squires, CCRP, HIT, Garry Shen, MD PhD, Versha Banerji, MD FRCP

Blood (2017) 130 (Supplement 1): 2545.

https://doi.org/10.1182/blood.V130.Suppl_1.2545.2545

Published: 2017

Journal Articles

The Cell Surface NADH Oxidase ENOX2 Is Highly Expressed in Chronic Myeloid Leukemia (CML): a Redox Protein As a Secreted Surrogate Biomarker and Druggable Target

Seda Baykal, Maud Voldoire, MD, Christophe Desterke, Nathalie Sorel, Hyacinthe Atchroue Johnson Ansah, Agnes Guerci-Bresler, MD, Jean-Claude Chomel, PharmD PhD, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD, PhD

Blood (2016) 128 (22): 3059.

https://doi.org/10.1182/blood.V128.22.3059.3059

Published: 2016

Journal Articles

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2016) 128 (22): 346.

https://doi.org/10.1182/blood.V128.22.346.346

Published: 2016

Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Blood (2016) 128 (22): 347.

https://doi.org/10.1182/blood.V128.22.347.347

Published: 2016

Journal Articles

Allele-specific DNA methylation reinforces PEAR1 enhancer activity

Benedetta Izzi, Mariaelena Pistoni, Katrien Cludts, Pinar Akkor, Diether Lambrechts, Catherine Verfaillie, Peter Verhamme, Kathleen Freson, Marc F. Hoylaerts

Blood (2016) 128 (7): 1003–1012.

https://doi.org/10.1182/blood-2015-11-682153

Published: 2016

Includes: Supplemental data

Journal Articles

BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans

Song Wu, Zongdong Li, Dmitri V. Gnatenko, Beibei Zhang, Lu Zhao, Lisa E. Malone, Nedialka Markova, Timothy J. Mantle, Natasha M. Nesbitt, Wadie F. Bahou

Blood (2016) 128 (5): 699–709.

https://doi.org/10.1182/blood-2016-02-696997

Published: 2016

Includes: Supplemental data

Journal Articles

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Srikanth Gottipati, PhD, Shashank Rohatagi, PhD, Woonbok Chung, PhD, Pietro Taverna, PhD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD

Blood (2015) 126 (23): 2594.

https://doi.org/10.1182/blood.V126.23.2594.2594

Published: 2015

Journal Articles

Wdr1-Mediated Actin Reorganization Is Essential for Integrin αIIbβ3 Activation in Platelets

Swapan Kumar Dasgupta, PhD, Qi Da, PhD, Anhquyen Le, Miguel A. Cruz, PhD, Perumal Thiagarajan, MD

Blood (2015) 126 (23): 2231.

https://doi.org/10.1182/blood.V126.23.2231.2231

Published: 2015

Journal Articles

Epigenetic Disruption of ZEB1 Binding Causes Constitutive Activation of IL-15 in Cutaneous T-Cell Lymphoma

Anjali Mishra, PhD, Sonya Kwiatkowski, Laura Sullivan, Leah Grinshpun, Giandomenico Russo, MD PhD, Pierluigi Porcu, MD, Michael A. Caligiuri, MD

Blood (2015) 126 (23): 3635.

https://doi.org/10.1182/blood.V126.23.3635.3635

Published: 2015

Journal Articles

Therapeutic Potential of Beta-Nicotinamide Adenine Dinucleotide to Reverse Endothelial Barrier Dysfunction in Sickle Cell Mouse Model

Nagavedi S Umapathy, PhD, Levi C Makala, DVM, MBA, PhD, Mayuko Takezaki, MS, Betty Pace, MD

Blood (2015) 126 (23): 969.

https://doi.org/10.1182/blood.V126.23.969.969

Published: 2015

Journal Articles

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

Dina Stroopinsky, PhD, Athalia Rachel Pyzer, MD, Kristen A Palmer, Maxwell D Coll, Michal Bar-Natan, MD, Hasan Rajabi, PhD, Poorvi Somaiya, MSc, Katarina Luptakova, MD, Salvia Jain, MD, Malgorzata McMasters, MD, James D. Levine, MD, Jon Arnason, MD, Pietro Taverna, PhD, Donald Kufe, MD, David Avigan, MD, Jacalyn Rosenblatt, MD

Blood (2014) 124 (21): 2303.

https://doi.org/10.1182/blood.V124.21.2303.2303

Published: 2014

Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2014) 124 (21): 529.

https://doi.org/10.1182/blood.V124.21.529.529

Published: 2014

NARROW

U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia

Inflammatory consequences of inherited disorders affecting neutrophil function

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Normal Hematopoiesis Is Dependent on the Expression of U2af1, a Spliceosome Gene Commonly Mutated in MDS

Whole Genome Sequencing Reveals the Extent of Structural Variants in Multiple Myeloma and Identifies Recurrent Mutational Hotspots within the Non-Coding Regions

Importance of Mitochondrial Metabolism As a Selective Therapeutic Approach in Chronic Lymphocytic Leukemia Patients

The Cell Surface NADH Oxidase ENOX2 Is Highly Expressed in Chronic Myeloid Leukemia (CML): a Redox Protein As a Secreted Surrogate Biomarker and Druggable Target

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Allele-specific DNA methylation reinforces PEAR1 enhancer activity

BLVRB redox mutation defines heme degradation in a metabolic pathway of enhanced thrombopoiesis in humans

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Wdr1-Mediated Actin Reorganization Is Essential for Integrin αIIbβ3 Activation in Platelets

Epigenetic Disruption of ZEB1 Binding Causes Constitutive Activation of IL-15 in Cutaneous T-Cell Lymphoma

Therapeutic Potential of Beta-Nicotinamide Adenine Dinucleotide to Reverse Endothelial Barrier Dysfunction in Sickle Cell Mouse Model

Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only